Momentum is exceptionally favorable and reflects a sharp acceleration in the market’s perception of the company story. Recent trading dynamics suggest a stock supported by high expectations around the pipeline, but this kind of rapid advance also implies significant sensitivity to any clinical or regulatory disappointment. For retail investors, the case presents an aggressive profile, attractive as long as the development thesis remains validated by medical updates and upcoming clinical milestones.